Do you have head and neck cancer or soft tissue sarcoma? Are you planning to have surgery to remove your tumor? You may be able to participate in a research study to determine which therapies may be best for future patients. Compensation provided.

The purpose of this study is to look at the effectiveness of a combination of treatments, polatuzumab vedotin with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) at treating relapsed or refractory diffuse large B-cell lymphoma.

The purpose of this study is to better understand how young adults (ages 18 - 39) who have had cancer use entertainment media during and after cancer treatment.

Do you have glioblastoma? Has your cancer either come back or did not improve after the treatments you received? If so, you may be eligible to participate in this gene therapy research study that wants to learn if a new way to modify your immune cells for use as possible treatment is safe and at what dose.

Do you have a type of cancer known as Nonseminmatous Germ Cell Tumor (NSGCT)? Has your cancer come back, or not get better with the last treatment you received? If so, you may be able to participate in a gene therapy study to see if we can use your body's own immune cells as a treatment for your NSGCT.

In this study, we want to use an online survey for people newly diagnosed with metastatic breast cancer to ask questions about physical and emotional health. We hope to use the results of this survey to design a program to help future patients tolerate treatment better.

Have you been diagnosed with Leukemia and are looking for another treatment option? In this study we are looking to see if the study drug DSP-5336 can help control Leukemia or achieve remission.

Have you been diagnosed with advanced unresectable pancreatic cancer. If so, you may be able to take part in a research study looking at the safety and tolerability of olaparib in combination with durvalumab and radiation therapy in patients with pancreatic cancer.

Have you been diagnosed with locally advanced head and neck squamous cell carcinoma? If so, you may be able to participate in a research study to evaluate whether pembrolizumab and olaparib given before and after chemoradiotherapy can improve 1-year progression free survival.

African American communities have been disproportionately affected by the burdens of cancer, yet their experiences and voices remain underrepresented in health research. In this study, we want to understand the experiences and perspectives of African American/Black individuals who support or care for their loved ones diagnosed with cancer.